Booster: Activating the proteasome to degrade misfolded proteins

In an era where increasing numbers of companies are seeking to drag specific proteins to the proteasome for degradation, newly launched Booster sees value in revving up the proteasome broadly. The idea is to break down multiple misfolded proteins, not just one.

Booster Therapeutics GmbH launched Thursday with a $15 million seed round led by Apollo and Novo Holdings to develop small molecules that bind the 20S proteasome and accelerate its processing of any misfolded protein present, reducing the opportunity of the proteins to aggregate...